Source-grounded facts extracted from NU SKIN ENTERPRISES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Steven K. Hatchett resigned as Executive Vice President and Chief Product Officer at NU SKIN ENTERPRISES, INC..
“Steven K. Hatchett notified the Company that, due to family health circumstances, he determined to resign from his position as Executive Vice President and Chief Product Officer, effective as of May 8, 2026.”
NU SKIN ENTERPRISES, INC. reported the three-month period ended March 31, 2026 results: revenue $320.6 million, EPS $0.04 or $0.14 excluding certain charges. Guidance reaffirmed.
“7, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)% • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale”
NU SKIN ENTERPRISES, INC. incurred credit facility of $175 million term loan facility and a $75 million revolving credit facility with Bank of America, N.A. at Term SOFR plus an initial spread of 1.75% per annum maturing five years.
“The Credit Agreement provides for a $175 million term loan facility and a $75 million revolving credit facility, each with a term of five years”
NU SKIN ENTERPRISES, INC. amended Credit Agreement with Bank of America, N.A., as Administrative Agent, and the Lenders from time to time party thereto valued at $175 million term loan facility and a $75 million revolving credit facility (effective 2026-03-27).
“On March 27, 2026 (the “Closing Date”), Nu Skin Enterprises, Inc. (the “Company”) entered into that certain Second Amendment and Restatement Agreement in connection with the Second Amended and Restated Credit Agreement (the “Credit Agreement”) by and among the Company, as Borrower, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, which amends and restates the Company’s existing amended and restated credit agreement, dated as of June 14, 2022 (as amended, supplemented or otherwise modified prior to the Closing Date, the “Existing Credit Agreement”).”
Zheqing (Simon) Shen departed as Director at NU SKIN ENTERPRISES, INC..
“On March 5, 2025, Zheqing (Simon) Shen informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided not to stand for re-election to the Company’s Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders due to other professional commitments.”
Mark A. Zorko was appointed as Director at NU SKIN ENTERPRISES, INC..
“On September 10, 2024, the Board of Directors (the “Board”) of Nu Skin Enterprises, Inc. (the “Company”) appointed Mark A. Zorko as a director of the Company”
NU SKIN ENTERPRISES, INC. reported the three-month period ended March 31, 2024 results: revenue $417.3 million, EPS $(0.01) or $0.09 excluding restructuring charges. Guidance reaffirmed.
“Nu Skin Enterprises Reports First Quarter Results PROVO, Utah — May 8, 2024 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter results in line with guidance. Executive Summary Q1 2024 vs. Prior-year Quarter Revenue $417.3 million; (13.3)% • (3.8)% FX impact or $(18.2) million • Rhyz revenue $62.5 million; 57.5% Earnings Per Share (EPS) $(0.01) or $0.09 excluding restructuring charges compared to $0.23 or $0.37 excluding restructuring charges Customers 875,261; (19)% Paid Affiliates 154,171; (30)% or (14)% excluding an adjustment to eligibility requirements Sales Leaders 38,609; (12)%”
Andrew Lipman retired as Director at NU SKIN ENTERPRISES, INC..
“On March 15, 2024, Andrew Lipman informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided to retire from the Company’s Board of Directors (the “Board”) and will not stand for re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders.”
NU SKIN ENTERPRISES, INC. reported Full-year 2024 results: revenue $1.73 to $1.87 billion, EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP. Guidance reaffirmed.
“2024 Revenue $1.73 to $1.87 billion; (12)% to (5)% • Approximately (1)% FX impact 2024 EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP”
NU SKIN ENTERPRISES, INC. reported Q1 2024 results: revenue $400 to $435 million, EPS $(0.07) to $0.03. Guidance reaffirmed.
“Q1 2024 Revenue $400 to $435 million; (17)% to (10)% • Approximately (3) to (2)% FX impact Q1 2024 EPS $(0.07) to $0.03 or $0.00 to $0.10 non-GAAP”
NU SKIN ENTERPRISES, INC. reported financial results for the three-month and annual periods ended December 31, 2023.
“On February 14, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information.”
Joseph Chang departed as Chief Scientific Officer at NU SKIN ENTERPRISES, INC..
“Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.”
NU SKIN ENTERPRISES, INC.: Board adopted Fifth Amended and Restated Bylaws effective February 5, 2024, with updates to align with DGCL, proxy rules, advance notice procedures, and director resignation requirements (effective 2024-02-05).
“On February 5, 2024, the Board of Directors of Nu Skin Enterprises, Inc. (the “Company”) approved and adopted the Fifth Amended and Restated Bylaws of the Company (as so amended and restated, the “Bylaws”), which became effective upon such approval and adoption.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.